Comparative Pharmacology
Head-to-head clinical analysis: GABLOFEN versus RELA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GABLOFEN versus RELA.
GABLOFEN vs RELA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GABLOFEN (baclofen) is a GABA-B receptor agonist that reduces spinal reflex transmission and inhibits excitatory neurotransmitter release.
RELA (Carisoprodol) is a centrally acting muscle relaxant that modulates GABA-A receptor activity and blocks interneuronal activity in the descending reticular formation and spinal cord, resulting in muscle relaxation without directly affecting the neuromuscular junction. Its metabolite, meprobamate, contributes to anxiolytic and sedative effects.
10 mg orally three times daily, may increase by 10 mg/day every 3 days to a maximum of 80 mg/day (20 mg four times daily).
Adults: 250-350 mg orally 3-4 times daily.
None Documented
None Documented
Terminal half-life 5-7 hours; clinically relevant for dosing interval of every 6-8 hours.
Terminal elimination half-life approximately 20–30 hours; prolonged in elderly and renal impairment
Renal: 70-80% unchanged; biliary/fecal: <5% as metabolites. Total clearance 2.5-3.0 L/h.
Primarily renal excretion of unchanged drug and metabolites; 70% to 80% eliminated via urine, remainder biliary/fecal
Category C
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant